Scrip sat down with Kite Pharma EVP Cindy Perettie to talk about the program that Gilead is running with Tennessee Oncology to bring CAR-T therapy into the community setting.

CEO Daniel O’Day highlighted Gilead’s large pipeline and relative safety from patent expirations over the next few years in the company’s Q1 earnings call.

They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.

The drug maker provided updates at ASH on newer agents, including a GPRC5D-directed CAR-T therapy, a member of the CELMoD class and its entry into an increasingly crowded BCMA bispecific ring.